- Home
- GCTK
GCTK
GlucoTrack Inc.
as 06-05-2025 4:00pm EST
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | RUTHERFORD |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $62.60 | Next Earning Date: | 06-17-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GlucoTrack Inc. News
GCTK Breaking Stock News: Dive into GCTK Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
9 days ago
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
GlobeNewswire
17 days ago
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
GlobeNewswire
23 days ago
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Medical Device Network
23 days ago
Glucotrack gains HREC approval for clinical study of CBGM device
GlobeNewswire
24 days ago
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
GlobeNewswire
2 months ago
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
GlobeNewswire
2 months ago
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Compare GCTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GCTK GlucoTrack Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.